Table 3. Patient characteristics in anthracycline- and nonanthracycline-treated patients (PTCL-NOS/AITL histologies).
|
PTLC-NOS/AITL |
|||||
|---|---|---|---|---|---|
|
Anthracycline (n=164) |
Nonanthracycline (n=27) |
P-value | |||
| No. | (%)a | No. | (%)a | ||
| Age | |||||
| ⩽60 | 85 | 52 | 9 | 33 | 0.7 |
| >60 | 79 | 48 | 18 | 67 | |
| LDH | |||||
| Normal | 53 | 32 | 3 | 11 | 0.02 |
| >Normal | 82 | 50 | 18 | 67 | |
| ECOG PS | |||||
| ⩽1 | 87 | 53 | 10 | 37 | 0.1 |
| >1 | 50 | 30 | 12 | 44 | |
| Extranodal site | |||||
| ⩽1 | 65 | 40 | 12 | 44 | 0.4 |
| >1 | 58 | 35 | 7 | 26 | |
| Ann Arbor stage | |||||
| I/II | 26 | 16 | 1 | 4 | 0.05 |
| III/IV | 135 | 82 | 26 | 96 | |
| IPI | |||||
| 0–2 Risk factors | 45 | 27 | 3 | 11 | 0.02 |
| 3–5 Risk factors | 85 | 52 | 21 | 78 | |
| Histology | |||||
| PTCL-NOS | 105 | 64 | 20 | 74 | 0.3 |
| AITL | 59 | 36 | 7 | 26 | |
| Front-line treatment | |||||
| Multiagent | 164 | 100 | 27 | 100 | — |
| Nonanthracycline | |||||
| Conventional therapyb | — | — | 13 | 48 | — |
| Salvage therapyc | — | — | 9 | 33 | — |
| Palliative therapyd | — | — | 5 | 19 | |
| Anthracycline based | |||||
| CHOP | 154 | 94 | — | — | — |
| Non-CHOP | 10 | 6 | — | — | |
| Stem cell transplant | |||||
| Autologous | 27 | 16 | 0 | 0 | 0.03 |
| Allogeneic | 14 | 9 | 2 | 7 | |
Abbreviations: AITL, angioimmunoblastic T-cell lymphoma; CHOP, cyclophosphamide/doxorubicin/vincristine/prednisone; ECOG PS, Eastern Cooperative Oncology Group Performance Status; IPI, International Prognostic Index; LDH, lactate dehydrogenase; PTCL-NOS, peripheral T-cell lymphoma-not otherwise specified.
a
Because of missing values, characteristic totals do not always sum 100%.
b
Conventional regimens included CVP, CEPP, COEP, GemOx, PEGS and variations.
c
Salvage regimens included ESHAP, ICE and DHAP.
d
Palliative regimens included methylprednisolone/nitrogen mustard, and alkylating agent/prednisone.